# A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

> **NCT04252768** · PHASE1 · WITHDRAWN · sponsor: **Immutep S.A.S.**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Eftilagimod Alpha
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04252768
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2025-06
- **Final completion:** 2026-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Replaced by other study NCT05747794
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252768, "A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04252768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*